Skip to main content
logo
AstraZeneca PLC (AZN)
NYSE: AZN · Real-Time Price · USD
190.02
-3.10 (-1.61%)
At close: Jul 8, 2026, 4:00 PM EDT
189.01
-1.01 (-0.53%)
After-hours: Jul 8, 2026, 5:11 PM EDT

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Oncology Revenue
26.77B25.62B20.28B
Oncology Revenue Growth
4.50%26.35%18.26%
BioPharmaceuticals: Cardiovascular, Renal & Metabolism PR (CVRM) Revenue
12.77B12.77B12.45B
BioPharmaceuticals: Cardiovascular, Renal & Metabolism PR (CVRM) Revenue Growth
-0.06%2.62%17.60%
BioPharmaceuticals: Respiratory & Immunology PR (R&I) Revenue
9.10B8.87B7.42B
BioPharmaceuticals: Respiratory & Immunology PR (R&I) Revenue Growth
2.64%19.55%21.43%
BioPharmaceuticals Infectious Disease PR (ID) Revenue
1.23B1.27B1.06B
BioPharmaceuticals Infectious Disease PR (ID) Revenue Growth
-3.39%19.85%4.54%
Rare Disease Revenue
9.50B9.13B8.67B
Rare Disease Revenue Growth
4.14%5.28%11.64%
Other Medicines Revenue
969.00M988.00M1.07B
Other Medicines Revenue Growth
-1.92%-7.92%-8.76%
Collaboration Revenue
102.00M99.00M3.14B
Collaboration Revenue Growth
3.03%-96.84%55.05%
Revenue (Total)
60.44B58.74B54.07B
Revenue (Total) Growth
2.89%8.63%18.04%

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
UK Revenue
-4.36B4.74B
UK Revenue Growth
--8.04%40.74%
Rest of Europe Revenue
-13.46B11.70B
Rest of Europe Revenue Growth
-14.97%20.34%
The Americas Revenue
-27.56B24.99B
The Americas Revenue Growth
-10.28%20.31%
Asia, Africa & Australasia Revenue
-13.37B12.64B
Asia, Africa & Australasia Revenue Growth
-5.75%5.81%
Revenue (Total)
60.44B58.74B54.07B
Revenue (Total) Growth
2.89%8.63%18.04%

EBIT by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
UK Operating Profit
-7.07B2.68B
UK Operating Profit Growth
-163.66%303.01%
Rest of Europe Operating Profit
-5.23B5.92B
Rest of Europe Operating Profit Growth
--11.66%21.27%
The Americas Operating Profit
-440.00M423.00M
The Americas Operating Profit Growth
-4.02%-71.71%
Asia, Africa & Australasia Operating Profit
-1.00B976.00M
Asia, Africa & Australasia Operating Profit Growth
-2.87%-14.98%
Operating Income (Total)
14.32B13.74B10.00B
Operating Income (Total) Growth
4.16%37.39%22.09%

Capital Expenditures by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
UK Assets Acquired
1.76B582.00M
UK Assets Acquired Growth
202.23%-28.32%
Rest of Europe Assets Acquired
2.81B2.23B
Rest of Europe Assets Acquired Growth
26.47%25.71%
The Americas Assets Acquired
1.88B3.93B
The Americas Assets Acquired Growth
-52.18%103.90%
Asia, Africa & Australasia Assets Acquired
557.00M1.39B
Asia, Africa & Australasia Assets Acquired Growth
-60.04%1091.45%